James F. Oliviero III
2016
In 2016, James F. Oliviero III earned a total compensation of $2.4M as Chief Executive Officer and President at Checkpoint Therapeutics, a 19% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $197,500 |
|---|---|
| Salary | $395,000 |
| Stock Awards | $1,764,750 |
| Total | $2,357,250 |
Oliviero received $1.8M in stock awards, accounting for 75% of the total pay in 2016.
Oliviero also received $197.5K in non-equity incentive plan and $395K in salary.
Rankings
In 2016, James F. Oliviero III's compensation ranked 4,166th out of 14,075 executives tracked by ExecPay. In other words, Oliviero earned more than 70.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,166 out of 14,075 | 70th |
Division Manufacturing | 1,458 out of 5,489 | 73rd |
Major group Chemicals And Allied Products | 440 out of 1,895 | 77th |
Industry group Drugs | 319 out of 1,538 | 79th |
Industry Pharmaceutical Preparations | 250 out of 1,176 | 79th |
Source: SEC filing on April 28, 2017.
Oliviero's colleagues
We found one more compensation record of an executive who worked with James F. Oliviero III at Checkpoint Therapeutics in 2016.
2016
William Gray
Checkpoint Therapeutics
Vice President, Finance and Accounting
News
Checkpoint Therapeutics CEO James Oliviero's 2023 pay slips 20% to $1.6M
April 2, 2024
Checkpoint Therapeutics CEO James Oliviero's 2022 pay slips 11% to $2M
May 1, 2023
Checkpoint Therapeutics CEO James Oliviero's 2021 pay stays at $2.3M
April 29, 2022
Checkpoint Therapeutics CEO James Oliviero's 2020 pay slips 1% to $2.3M
April 30, 2021
Checkpoint Therapeutics CEO James Oliviero's 2019 pay rises 8% to $2.3M
April 24, 2020
Checkpoint Therapeutics CEO James Oliviero's 2018 pay jumps 230% to $2.1M
April 30, 2019